The paper's citation list
No. | The paper's citation list |
|---|
1 | Analytical and clinical comparison between two different analytical methods for the measurement of circulating insulin in patients with metabolic-dysfunction associated steatotic liver disease. 2024;36: doi: 10.23736/S2724-542X.24.03175-4 |
2 | Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD. 2025;5: doi: 10.1038/s43856-025-00821-x |
3 | Metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: general provisions. 2024;19:107 doi: 10.22141/2224-0551.19.2.2024.1683 |
4 | Feasibility of Serum Galectin-1 as a Diagnostic Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study on a Segment of the Chinese Population Using Convenience Sampling. 2025;13:425 doi: 10.3390/biomedicines13020425 |
5 | From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease—A systematic review. 2025; doi: 10.1111/eci.70075 |
6 | Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. 2024;4: doi: 10.20517/mtod.2024.07 |
7 | MAFLD vs. MASLD: a year in review. 2025;1 doi: 10.1080/17446651.2025.2492767 |
8 | Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response. 2024;4: doi: 10.20517/mtod.2024.64 |
9 | Does an Aspirin a Day Take the MASLD Away?. 2024;41:2559 doi: 10.1007/s12325-024-02885-y |
10 | Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease. 2025;31: doi: 10.3748/wjg.v31.i3.100393 |
11 | Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence. 2025;5: doi: 10.20517/mtod.2025.04 |
12 | Cytokeratin 18 in nonalcoholic fatty liver disease: value and application. 2024;24:1009 doi: 10.1080/14737159.2024.2413941 |
13 | Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1. 2024;4: doi: 10.20517/mtod.2024.48 |
14 | The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner?. 2024;44:1564 doi: 10.1111/liv.15950 |
15 | From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction. 2024; doi: 10.20517/mtod.2024.39 |
16 | Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. 2025;22:314 doi: 10.1038/s41575-025-01045-z |
